CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation for CNS Immune Priv…

This hypothesis proposes that selective upregulation of CXCL12 in astrocytes can restore CNS immune privilege by disrupting the CCL2 chemokine gradient that drives pathogenic monocyte infiltration. Rather than depleting CCR2+ monocytes systemically, this approach targets the upstream chemotactic signals by enhancing the competing CXCL12/CXCR4 axis specifically within CNS parenchyma. Astrocytes constitutively express low levels of CXCL12, which normally contributes to maintaining CNS homeostasis and supporting resident microglia positioning. By pharmacologically or genetically enhancing astrocytic CXCL12 production, we hypothesize that infiltrating monocytes will be redirected away from inflammatory foci, as CXCL12 can competitively bind and sequester monocytes that co-express CXCR4. This mechanism would preserve systemic monocyte populations while creating a local CNS environment that favors retention of homeostatic immune cells over inflammatory infiltrates. The intervention would involve astrocyte-specific CXCL12 overexpression using GFAP-driven vectors or small molecule enhancers of CXCL12 transcription. Evidence would focus on measuring changes in monocyte trafficking patterns, astrocytic CXCL12 expression levels, and restoration of blood-brain barrier integrity markers. This approach maintains the core goal of restoring CNS immune privilege but shifts from a depletion strategy to a redirection strategy, targeting the chemokine microenvironment rather than the responding cell population directly.